Skip to main content
Jade Biosciences, Inc. logo

Jade Biosciences, Inc. — Investor Relations & Filings

Ticker · JBIO ISIN · US0080641071 US Professional, scientific and technical activities
Filings indexed 452 across all filing types
Latest filing 2025-12-19 Prospectus
Country US United States of America
Listing US JBIO

About Jade Biosciences, Inc.

https://jadebiosciences.com/

Jade Biosciences, Inc. is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases, inflammation, and immunology. The company aims to create transformative, disease-modifying treatments to address significant unmet medical needs and redefine the standard of care. Its pipeline features novel biologics, with the lead candidate, JADE101, being developed for the treatment of immunoglobulin A nephropathy (IgAN). JADE101 is an inhibitor of the cytokine APRIL (A PRoliferation-Inducing Ligand). The company's programs are based on discovery-stage assets licensed from Paragon Therapeutics.

Recent filings

Filing Released Lang Actions
424B3
Prospectus
2025-12-19 English
8-K
Regulatory Filings
2025-12-15 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-11-14 English
S-1
Registration Form
2025-11-14 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-11-14 English
10-Q
Interim / Quarterly Report Q3 2025
2025-11-14 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.